{"success":true,"data":{"pressRelease":{"id":"168619","rtpr_id":"nGNX7PY0JQ-20261014","ticker":"AQST","exchange":"NASDAQ","all_tickers":["AQST","ETON"],"title":"Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film","author":"Globe Newswire","published_at":"2026-10-14T10:50:00.149Z","article_body":"* Differentiated, portable buccal film would offer patients and caregivers an\nalternative to existing nasal and rectal seizure rescue treatments, a market\nopportunity that exceeds $450 million annually in the U.S.\n* Patient market research demonstrated strong preference for buccal film, with\n71% of surveyed patients preferring film versus 13% for nasal spray, assuming\nequivalent efficacy\n* Anticipated commercial launch in April 2027, subject to final FDA approval,\nprovides a potential near-term growth opportunity and new commercial platform\nin neurology\n* LIBERVANT has received Orphan Drug Designation and has issued patent\nprotection extending into 2038, with additional patent applications pending\nwith the U.S. Patent and Trademark Office\nDEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton\nPharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative\npharmaceutical company focused on developing and commercializing treatments\nfor rare diseases, and Aquestive Therapeutics, Inc. (“Aquestive”) (Nasdaq:\nAQST), a pharmaceutical company advancing medicines to bring meaningful\nimprovement to patients’ lives through innovative science and delivery\ntechnologies, today announced that they have entered into an exclusive license\nagreement and a supply agreement covering the United States and its\nterritories for LIBERVANT(®) (diazepam) buccal film, an Orphan\nDrug-designated, differentiated treatment for seizure clusters in patients\nwith epilepsy. Eton anticipates commercial availability of LIBERVANT in April\n2027, subject to final U.S. Food and Drug Administration (FDA) approval.\n\nThe agreement grants Eton exclusive U.S. commercialization rights to LIBERVANT\nand adds a new growth driver to Eton’s expanding rare disease portfolio. The\nproduct builds on Eton’s experience commercializing differentiated dosage\nforms, engaging specialist physicians, and supporting patients and caregivers\nthrough treatment education, advocacy, and programs designed to maximize\ntherapy access and minimize affordability barriers.\n\n“LIBERVANT marks an important expansion of our portfolio into neurology and\nrepresents a compelling opportunity to bring an orphan-designated,\ndifferentiated therapy to patients,” said Sean Brynjelsen, Chief Executive\nOfficer of Eton Pharmaceuticals. “The U.S. seizure rescue market exceeds\n$450 million annually, and we believe LIBERVANT’s innovative buccal film\ntechnology, together with Eton’s experience commercializing differentiated\ndosage forms, positions us well to compete in this established market.\n\n“By pairing Aquestive’s proprietary technology with Eton’s commercial\ncapabilities and patient support services, we aim to provide physicians,\npatients, and caregivers an additional treatment option while building another\ndurable source of growth for our shareholders. This agreement advances our\nstrategy of acquiring and commercializing differentiated medicines, and we are\nexcited to work with Aquestive toward an anticipated April 2027 launch,”\nconcluded Brynjelsen.\n\n“Today marks an important new chapter for LIBERVANT and for the epilepsy\ncommunity,” said Daniel Barber, President and Chief Executive Officer of\nAquestive Therapeutics. “I am confident that Eton’s focus on specialty\nmedicines and patient access will be essential as we work toward making\nLIBERVANT available to the epilepsy community. This collaboration brings\ntogether complementary capabilities and provides a focused path to U.S.\ncommercialization, allowing us to advance a product with the potential to\naddress the needs of patients and caregivers seeking an alternative to nasal\nand rectal delivery.”\n\nBuilding on Eton’s Rare Disease Foundation\n\nLIBERVANT’s Orphan Drug Designation and specialist treatment setting\ncomplement Eton’s focus on medicines requiring targeted education, patient\nsupport, and close engagement with healthcare professionals and patient\nadvocacy groups. The agreement also builds on Eton’s experience supporting\npediatric patients and families, where treatment decisions often involve\ncaregivers and confidence in administration is important.\n\nEton plans to establish a dedicated neurology team supported by its existing\ncommercial infrastructure. Its commercialization approach will draw on\nexperience acquiring and relaunching specialty medicines, including INCRELEX,\nGALZIN, and HEMANGEOL, as well as established capabilities in advocacy\npartnerships, community engagement, and treatment education.\n\nRegulatory Status and Anticipated Launch\n\nThe U.S. FDA granted LIBERVANT Orphan Drug Designation in November 2016.\nLIBERVANT currently has been granted tentative approval by the U.S. FDA for\nthe acute treatment of intermittent, stereotypic episodes of frequent seizure\nactivity (i.e., seizure clusters, acute repetitive seizures) that are distinct\nfrom a patient’s usual seizure pattern in patients with epilepsy 2 to 5\nyears of age and 12 years of age and above. The product is expected to become\neligible for full approval in patients 12 years of age and above following the\nscheduled expiration of VALTOCO(®)’s orphan drug exclusivity on January 10,\n2027. In addition, a Type 9 New Drug Application (NDA) is under review with\nthe U.S. FDA to add ages 6 to 11 to the product’s label. The NDA has a\nPrescription Drug User Fee Act (PDUFA) target action date of March 29, 2027.\nIf approved, the application would expand the potential labeled population to\npatients ages 6 and older. Eton anticipates the product being commercially\navailable in April 2027, subject to final FDA approval.\n\nLIBERVANT has issued patent protection extending into 2038 and additional\npatent applications are pending with the U.S. Patent and Trademark Office.\n\nPatient Research Highlights the Importance of Portability and Treatment Choice\n\nThird-party market research highlights a gap between patients’ desire to\nkeep seizure-cluster medication close and their reported carrying habits.\nAmong 101 patients surveyed, 76% were somewhat or highly concerned about not\nhaving their medication within arm’s reach when away from home, yet only 34%\nreported always carrying it outside the home.\n\nAfter viewing a video comparing film and nasal-spray packaging, 71% preferred\nor strongly preferred that their physician prescribe the film, compared with\n13% for nasal spray, assuming both medicines worked equally well. These\nfindings underscore patients’ interest in portability and treatment choice\nand reflect stated preferences, rather than comparative clinical outcomes.\n\nAbout LIBERVANT\n\nLIBERVANT is a buccal film formulation of diazepam, a benzodiazepine,\ndeveloped for the acute treatment of seizure clusters that are distinct from a\npatient’s usual seizure pattern. The film is placed inside the cheek and\ndissolves without the need for a delivery device. LIBERVANT is intended as an\nintermittent rescue treatment and is not a replacement for daily maintenance\nantiseizure therapy. Its U.S. regulatory status and the age groups under\nreview are described above.\n\nImportant Safety Information \nDo not give Libervant™ to your child if your child is allergic to diazepam\nor any of the ingredients in Libervant or has an eye problem called acute\nnarrow angle glaucoma.\n\nWhat is the most important information I should know about Libervant?\n* Libervant is a benzodiazepine medicine. Taking benzodiazepines with opioid\nmedicines, alcohol, or other central nervous system (CNS) depressants\n(including street drugs) can cause severe drowsiness, breathing problems\n(respiratory depression), coma, and death. Get emergency help right away if\nany of the following happens: * shallow or slowed breathing,\n* breathing stops (which may lead to the heart stopping),\n* excessive sleepiness (sedation).\nDo not allow your child to drive a motor vehicle, operate heavy machinery, or\nride a bicycle until you know how taking Libervant with opioids affects your\nchild.\n* Risk of abuse, misuse, and addiction. Libervant is used in children 2 to 5\nyears of age. The unapproved use of Libervant has a risk for abuse, misuse,\nand addiction, which can lead to overdose and serious side effects including\ncoma and death.\n* Serious side effects including coma and death have happened in people who\nhave abused or misused benzodiazepines, including diazepam (the active\ningredient in Libervant). These serious side effects may also include\ndelirium, paranoia, suicidal thoughts or actions, seizures, and difficulty\nbreathing. Call your child’s healthcare provider or go to the nearest\nhospital emergency room right away if you get any of these serious side\neffects. * Your child can develop an addiction even if your child takes\nLibervant as prescribed by your child’s healthcare provider.\n* Give Libervant exactly as your child’s healthcare provider prescribed.\n* Do not share Libervant with other people.\n* Keep Libervant in a safe place and away from children.\n \n* Physical dependence and withdrawal reactions. Libervant is intended for use\nif needed in order to treat higher than usual seizure activity.\nBenzodiazepines, including Libervant, can cause physical dependence and\nwithdrawal reactions, especially if used daily. Libervant is not intended for\ndaily use. * Do not suddenly stop giving Libervant to your child without\ntalking to your child’s healthcare provider. Stopping Libervant suddenly can\ncause serious and life-threatening side effects, including, unusual movements,\nresponses, or expressions, seizures that will not stop (status epilepticus),\nsudden and severe mental or nervous system changes, depression, seeing or\nhearing things that others do not see or hear, homicidal thoughts, an extreme\nincrease in activity or talking, losing touch with reality, and suicidal\nthoughts or actions. Call your child’s healthcare provider or go to the\nnearest hospital emergency room right away if your child gets any of these\nsymptoms.\n* Some people who suddenly stop benzodiazepines have symptoms that can last\nfor several weeks to more than 12 months including, anxiety, trouble\nremembering, learning, or concentrating, depression, problems sleeping,\nfeeling like insects are crawling under your skin, weakness, shaking, muscle\ntwitching, burning, or prickling feeling in your hands, arms, legs or feet,\nand ringing in your ears.\n* Physical dependence is not the same as drug addiction. Your child’s\nhealthcare provider can tell you more about the differences between physical\ndependence and drug addiction.\n \n* Do not give your child more Libervant than prescribed or give Libervant more\noften than prescribed.\nLibervant can make your child sleepy or dizzy and can slow your child’s\nthinking and motor skills.\n* Do not allow your child to drive a motor vehicle, operate machinery, or ride\na bicycle until you know how Libervant affects your child.\n* Do not give other drugs that may make your child sleepy or dizzy while\ntaking Libervant without first talking to your child’s healthcare provider.\nWhen taken with drugs that cause sleepiness or dizziness, Libervant may make\nyour child’s sleepiness or dizziness much worse.\nLike other antiepileptic medicines, Libervant may cause suicidal thoughts or\nactions in a small number of people, about 1 in 500.\n* Call a healthcare provider right away if your child has any of these\nsymptoms, especially if they are new, worse, or worry you: * thoughts about\nsuicide or dying\n* new or worse depression\n* feeling agitated or restless\n* trouble sleeping (insomnia)\n* acting aggressive, being angry or violent\n* other unusual changes in behavior or mood\n* attempts to commit suicide\n* new or worse anxiety or irritability\n* an extreme increase in activity and talking (mania)\n* new or worse panic attacks\n* acting on dangerous impulses\n \n* Pay attention to any changes, especially sudden changes in mood, behaviors,\nthoughts, or feelings.\n* Keep all follow-up visits with your child’s healthcare provider as\nscheduled.\n* Call your child’s healthcare provider between visits as needed, especially\nif you are worried about symptoms. Suicidal thoughts or actions can be caused\nby things other than medicines. If your child has suicidal thoughts or\nactions, your child’s healthcare provider may check for other causes.\nWhat are the possible side effects of Libervant?\n* The most common side effects of Libervant are sleepiness and headache.\n* These are not all the possible side effects of Libervant.\n* Call your doctor for medical advice about side effects. You may report side\neffects to FDA at 1-800-FDA-1088.\nFor more information about Libervant, talk to your doctor, and see Product\nInformation: Medication Guide and Instructions For Use\n(https://www.globenewswire.com/Tracker?data=6GDKvCYt8AjpZqgTljrMkLe0kz_VHYDxMn4XNihlt41K39ZSY2ijSunTmy8W_y0qdL_dAgGtfXmA5m0OWDA4ue1bwcex8agRyxvW5IQMoR-kc-cTmfiX6468E52kaqGe_ZT2oPZi6J9jkYRpKLfW4EIe2idTvUofGdC5D2jpUZkopaMIyMMXrQU68RNBXcxI85kVxDmqoJiDQvzxYTGq3Tuuov6H_8JNu9fqyoOeoYE=).\n\nAbout Eton Pharmaceuticals\n\nEton is an innovative pharmaceutical company focused on developing and\ncommercializing treatments for rare diseases. The Company currently has eleven\ncommercial rare disease products: KHINDIVI(®) (hydrocortisone), INCRELEX(®)\n(mecasermin), ALKINDI SPRINKLE(®) (hydrocortisone), DESMODA(™)\n(desmopressin acetate), GALZIN(®) (zinc acetate), HEMANGEOL(®) (propranolol\nhydrochloride), PKU GOLIKE(®), IMPAVIDO(®) (miltefosine), Carglumic Acid,\nBetaine Anhydrous, and Nitisinone. The Company has five additional product\ncandidates in late-stage development: AMGLIDIA(®) (glyburide), ASN-001,\nET-700, ET-800, and ZENEO(®) hydrocortisone autoinjector. For more\ninformation, please visit our website at www.etonpharma.com.\n\nAbout Aquestive\n\nAquestive is a pharmaceutical company advancing medicines to bring meaningful\nimprovement to patients' lives through innovative science and delivery\ntechnologies. The worldwide leader in delivering trusted, quality medications\non oral film, Aquestive operates as both a developer of its own proprietary\nproducts and a Contract Development and Manufacturing Organization (CDMO) for\nlicensees, with its headquarters in New Jersey and U.S.-based manufacturing\nfacilities in Indiana. The Company is the exclusive manufacturer of four\ncommercialized products marketed by its licensees across six continents using\nproprietary, best-in-class technologies like PharmFilm®. Aquestive's\nAdrenaVerse™ platform contains a library of more than 20 epinephrine\nprodrugs enabling the pursuit of various potential allergy and dermatological\nindications. The Company is advancing Anaphylm™ (dibutepinephrine)\nsublingual film for the treatment of severe allergic reactions, including\nanaphylaxis, and AQST-108 (epinephrine) topical gel for various potential\ndermatological conditions. For more information, visit Aquestive.com and\nfollow us on LinkedIn\n\nForward Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\napplicable securities laws, including statements regarding LIBERVANT’s\npotential commercial opportunity, contribution to Eton’s growth, anticipated\napproval and launch timing, potential label expansion, patent protection, and\ncommercialization plans, the potential receipt by Aquestive of upfront,\nmilestone and royalty payments, and Aquestive’s manufacture and supply of\nLIBERVANT. These statements reflect current expectations and involve risks and\nuncertainties that could cause actual results to differ materially. These\ninclude delays in or failure to obtain final FDA approval or label expansion;\nchanges in regulatory requirements or the effect of competing products’\nexclusivity; manufacturing or supply constraints; competition, pricing,\nreimbursement, and market acceptance; commercialization costs and execution;\nthe scope, validity, and enforceability of intellectual property rights;\nwhether and when milestone events are achieved, which depend on FDA approvals\nand Eton’s commercialization efforts; the amount of any royalties, which\ndepends on net sales; Eton’s right to terminate the license agreement; and\nAquestive’s ability to meet its supply obligations. Additional risks are\ndescribed in Eton’s and Aquestive’s filings with the Securities and\nExchange Commission. Neither company undertakes any obligation to update these\nstatements except as required by law.\n\nEton Investor Relations:\nLisa M. Wilson, In-Site Communications, Inc.\nT: 212-452-2793\nE: lwilson@insitecony.com\n\nAquestive Investor Relations:\nBrian Korb, astr partners\nbrian.korb@astrpartners.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/db07cafa-b35c-4d61-a1a1-d330caf67ad2)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7PY0JQ-20261014","title":"Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film","author":"Globe Newswire","ticker":"AQST","created":"2026-10-14T10:50:00.149Z","tickers":["AQST","ETON"],"exchange":"NASDAQ","article_body":"* Differentiated, portable buccal film would offer patients and caregivers an\nalternative to existing nasal and rectal seizure rescue treatments, a market\nopportunity that exceeds $450 million annually in the U.S.\n* Patient market research demonstrated strong preference for buccal film, with\n71% of surveyed patients preferring film versus 13% for nasal spray, assuming\nequivalent efficacy\n* Anticipated commercial launch in April 2027, subject to final FDA approval,\nprovides a potential near-term growth opportunity and new commercial platform\nin neurology\n* LIBERVANT has received Orphan Drug Designation and has issued patent\nprotection extending into 2038, with additional patent applications pending\nwith the U.S. Patent and Trademark Office\nDEER PARK, Ill. and WARREN, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Eton\nPharmaceuticals, Inc. (“Eton”) (Nasdaq: ETON), an innovative\npharmaceutical company focused on developing and commercializing treatments\nfor rare diseases, and Aquestive Therapeutics, Inc. (“Aquestive”) (Nasdaq:\nAQST), a pharmaceutical company advancing medicines to bring meaningful\nimprovement to patients’ lives through innovative science and delivery\ntechnologies, today announced that they have entered into an exclusive license\nagreement and a supply agreement covering the United States and its\nterritories for LIBERVANT(®) (diazepam) buccal film, an Orphan\nDrug-designated, differentiated treatment for seizure clusters in patients\nwith epilepsy. Eton anticipates commercial availability of LIBERVANT in April\n2027, subject to final U.S. Food and Drug Administration (FDA) approval.\n\nThe agreement grants Eton exclusive U.S. commercialization rights to LIBERVANT\nand adds a new growth driver to Eton’s expanding rare disease portfolio. The\nproduct builds on Eton’s experience commercializing differentiated dosage\nforms, engaging specialist physicians, and supporting patients and caregivers\nthrough treatment education, advocacy, and programs designed to maximize\ntherapy access and minimize affordability barriers.\n\n“LIBERVANT marks an important expansion of our portfolio into neurology and\nrepresents a compelling opportunity to bring an orphan-designated,\ndifferentiated therapy to patients,” said Sean Brynjelsen, Chief Executive\nOfficer of Eton Pharmaceuticals. “The U.S. seizure rescue market exceeds\n$450 million annually, and we believe LIBERVANT’s innovative buccal film\ntechnology, together with Eton’s experience commercializing differentiated\ndosage forms, positions us well to compete in this established market.\n\n“By pairing Aquestive’s proprietary technology with Eton’s commercial\ncapabilities and patient support services, we aim to provide physicians,\npatients, and caregivers an additional treatment option while building another\ndurable source of growth for our shareholders. This agreement advances our\nstrategy of acquiring and commercializing differentiated medicines, and we are\nexcited to work with Aquestive toward an anticipated April 2027 launch,”\nconcluded Brynjelsen.\n\n“Today marks an important new chapter for LIBERVANT and for the epilepsy\ncommunity,” said Daniel Barber, President and Chief Executive Officer of\nAquestive Therapeutics. “I am confident that Eton’s focus on specialty\nmedicines and patient access will be essential as we work toward making\nLIBERVANT available to the epilepsy community. This collaboration brings\ntogether complementary capabilities and provides a focused path to U.S.\ncommercialization, allowing us to advance a product with the potential to\naddress the needs of patients and caregivers seeking an alternative to nasal\nand rectal delivery.”\n\nBuilding on Eton’s Rare Disease Foundation\n\nLIBERVANT’s Orphan Drug Designation and specialist treatment setting\ncomplement Eton’s focus on medicines requiring targeted education, patient\nsupport, and close engagement with healthcare professionals and patient\nadvocacy groups. The agreement also builds on Eton’s experience supporting\npediatric patients and families, where treatment decisions often involve\ncaregivers and confidence in administration is important.\n\nEton plans to establish a dedicated neurology team supported by its existing\ncommercial infrastructure. Its commercialization approach will draw on\nexperience acquiring and relaunching specialty medicines, including INCRELEX,\nGALZIN, and HEMANGEOL, as well as established capabilities in advocacy\npartnerships, community engagement, and treatment education.\n\nRegulatory Status and Anticipated Launch\n\nThe U.S. FDA granted LIBERVANT Orphan Drug Designation in November 2016.\nLIBERVANT currently has been granted tentative approval by the U.S. FDA for\nthe acute treatment of intermittent, stereotypic episodes of frequent seizure\nactivity (i.e., seizure clusters, acute repetitive seizures) that are distinct\nfrom a patient’s usual seizure pattern in patients with epilepsy 2 to 5\nyears of age and 12 years of age and above. The product is expected to become\neligible for full approval in patients 12 years of age and above following the\nscheduled expiration of VALTOCO(®)’s orphan drug exclusivity on January 10,\n2027. In addition, a Type 9 New Drug Application (NDA) is under review with\nthe U.S. FDA to add ages 6 to 11 to the product’s label. The NDA has a\nPrescription Drug User Fee Act (PDUFA) target action date of March 29, 2027.\nIf approved, the application would expand the potential labeled population to\npatients ages 6 and older. Eton anticipates the product being commercially\navailable in April 2027, subject to final FDA approval.\n\nLIBERVANT has issued patent protection extending into 2038 and additional\npatent applications are pending with the U.S. Patent and Trademark Office.\n\nPatient Research Highlights the Importance of Portability and Treatment Choice\n\nThird-party market research highlights a gap between patients’ desire to\nkeep seizure-cluster medication close and their reported carrying habits.\nAmong 101 patients surveyed, 76% were somewhat or highly concerned about not\nhaving their medication within arm’s reach when away from home, yet only 34%\nreported always carrying it outside the home.\n\nAfter viewing a video comparing film and nasal-spray packaging, 71% preferred\nor strongly preferred that their physician prescribe the film, compared with\n13% for nasal spray, assuming both medicines worked equally well. These\nfindings underscore patients’ interest in portability and treatment choice\nand reflect stated preferences, rather than comparative clinical outcomes.\n\nAbout LIBERVANT\n\nLIBERVANT is a buccal film formulation of diazepam, a benzodiazepine,\ndeveloped for the acute treatment of seizure clusters that are distinct from a\npatient’s usual seizure pattern. The film is placed inside the cheek and\ndissolves without the need for a delivery device. LIBERVANT is intended as an\nintermittent rescue treatment and is not a replacement for daily maintenance\nantiseizure therapy. Its U.S. regulatory status and the age groups under\nreview are described above.\n\nImportant Safety Information \nDo not give Libervant™ to your child if your child is allergic to diazepam\nor any of the ingredients in Libervant or has an eye problem called acute\nnarrow angle glaucoma.\n\nWhat is the most important information I should know about Libervant?\n* Libervant is a benzodiazepine medicine. Taking benzodiazepines with opioid\nmedicines, alcohol, or other central nervous system (CNS) depressants\n(including street drugs) can cause severe drowsiness, breathing problems\n(respiratory depression), coma, and death. Get emergency help right away if\nany of the following happens: * shallow or slowed breathing,\n* breathing stops (which may lead to the heart stopping),\n* excessive sleepiness (sedation).\nDo not allow your child to drive a motor vehicle, operate heavy machinery, or\nride a bicycle until you know how taking Libervant with opioids affects your\nchild.\n* Risk of abuse, misuse, and addiction. Libervant is used in children 2 to 5\nyears of age. The unapproved use of Libervant has a risk for abuse, misuse,\nand addiction, which can lead to overdose and serious side effects including\ncoma and death.\n* Serious side effects including coma and death have happened in people who\nhave abused or misused benzodiazepines, including diazepam (the active\ningredient in Libervant). These serious side effects may also include\ndelirium, paranoia, suicidal thoughts or actions, seizures, and difficulty\nbreathing. Call your child’s healthcare provider or go to the nearest\nhospital emergency room right away if you get any of these serious side\neffects. * Your child can develop an addiction even if your child takes\nLibervant as prescribed by your child’s healthcare provider.\n* Give Libervant exactly as your child’s healthcare provider prescribed.\n* Do not share Libervant with other people.\n* Keep Libervant in a safe place and away from children.\n \n* Physical dependence and withdrawal reactions. Libervant is intended for use\nif needed in order to treat higher than usual seizure activity.\nBenzodiazepines, including Libervant, can cause physical dependence and\nwithdrawal reactions, especially if used daily. Libervant is not intended for\ndaily use. * Do not suddenly stop giving Libervant to your child without\ntalking to your child’s healthcare provider. Stopping Libervant suddenly can\ncause serious and life-threatening side effects, including, unusual movements,\nresponses, or expressions, seizures that will not stop (status epilepticus),\nsudden and severe mental or nervous system changes, depression, seeing or\nhearing things that others do not see or hear, homicidal thoughts, an extreme\nincrease in activity or talking, losing touch with reality, and suicidal\nthoughts or actions. Call your child’s healthcare provider or go to the\nnearest hospital emergency room right away if your child gets any of these\nsymptoms.\n* Some people who suddenly stop benzodiazepines have symptoms that can last\nfor several weeks to more than 12 months including, anxiety, trouble\nremembering, learning, or concentrating, depression, problems sleeping,\nfeeling like insects are crawling under your skin, weakness, shaking, muscle\ntwitching, burning, or prickling feeling in your hands, arms, legs or feet,\nand ringing in your ears.\n* Physical dependence is not the same as drug addiction. Your child’s\nhealthcare provider can tell you more about the differences between physical\ndependence and drug addiction.\n \n* Do not give your child more Libervant than prescribed or give Libervant more\noften than prescribed.\nLibervant can make your child sleepy or dizzy and can slow your child’s\nthinking and motor skills.\n* Do not allow your child to drive a motor vehicle, operate machinery, or ride\na bicycle until you know how Libervant affects your child.\n* Do not give other drugs that may make your child sleepy or dizzy while\ntaking Libervant without first talking to your child’s healthcare provider.\nWhen taken with drugs that cause sleepiness or dizziness, Libervant may make\nyour child’s sleepiness or dizziness much worse.\nLike other antiepileptic medicines, Libervant may cause suicidal thoughts or\nactions in a small number of people, about 1 in 500.\n* Call a healthcare provider right away if your child has any of these\nsymptoms, especially if they are new, worse, or worry you: * thoughts about\nsuicide or dying\n* new or worse depression\n* feeling agitated or restless\n* trouble sleeping (insomnia)\n* acting aggressive, being angry or violent\n* other unusual changes in behavior or mood\n* attempts to commit suicide\n* new or worse anxiety or irritability\n* an extreme increase in activity and talking (mania)\n* new or worse panic attacks\n* acting on dangerous impulses\n \n* Pay attention to any changes, especially sudden changes in mood, behaviors,\nthoughts, or feelings.\n* Keep all follow-up visits with your child’s healthcare provider as\nscheduled.\n* Call your child’s healthcare provider between visits as needed, especially\nif you are worried about symptoms. Suicidal thoughts or actions can be caused\nby things other than medicines. If your child has suicidal thoughts or\nactions, your child’s healthcare provider may check for other causes.\nWhat are the possible side effects of Libervant?\n* The most common side effects of Libervant are sleepiness and headache.\n* These are not all the possible side effects of Libervant.\n* Call your doctor for medical advice about side effects. You may report side\neffects to FDA at 1-800-FDA-1088.\nFor more information about Libervant, talk to your doctor, and see Product\nInformation: Medication Guide and Instructions For Use\n(https://www.globenewswire.com/Tracker?data=6GDKvCYt8AjpZqgTljrMkLe0kz_VHYDxMn4XNihlt41K39ZSY2ijSunTmy8W_y0qdL_dAgGtfXmA5m0OWDA4ue1bwcex8agRyxvW5IQMoR-kc-cTmfiX6468E52kaqGe_ZT2oPZi6J9jkYRpKLfW4EIe2idTvUofGdC5D2jpUZkopaMIyMMXrQU68RNBXcxI85kVxDmqoJiDQvzxYTGq3Tuuov6H_8JNu9fqyoOeoYE=).\n\nAbout Eton Pharmaceuticals\n\nEton is an innovative pharmaceutical company focused on developing and\ncommercializing treatments for rare diseases. The Company currently has eleven\ncommercial rare disease products: KHINDIVI(®) (hydrocortisone), INCRELEX(®)\n(mecasermin), ALKINDI SPRINKLE(®) (hydrocortisone), DESMODA(™)\n(desmopressin acetate), GALZIN(®) (zinc acetate), HEMANGEOL(®) (propranolol\nhydrochloride), PKU GOLIKE(®), IMPAVIDO(®) (miltefosine), Carglumic Acid,\nBetaine Anhydrous, and Nitisinone. The Company has five additional product\ncandidates in late-stage development: AMGLIDIA(®) (glyburide), ASN-001,\nET-700, ET-800, and ZENEO(®) hydrocortisone autoinjector. For more\ninformation, please visit our website at www.etonpharma.com.\n\nAbout Aquestive\n\nAquestive is a pharmaceutical company advancing medicines to bring meaningful\nimprovement to patients' lives through innovative science and delivery\ntechnologies. The worldwide leader in delivering trusted, quality medications\non oral film, Aquestive operates as both a developer of its own proprietary\nproducts and a Contract Development and Manufacturing Organization (CDMO) for\nlicensees, with its headquarters in New Jersey and U.S.-based manufacturing\nfacilities in Indiana. The Company is the exclusive manufacturer of four\ncommercialized products marketed by its licensees across six continents using\nproprietary, best-in-class technologies like PharmFilm®. Aquestive's\nAdrenaVerse™ platform contains a library of more than 20 epinephrine\nprodrugs enabling the pursuit of various potential allergy and dermatological\nindications. The Company is advancing Anaphylm™ (dibutepinephrine)\nsublingual film for the treatment of severe allergic reactions, including\nanaphylaxis, and AQST-108 (epinephrine) topical gel for various potential\ndermatological conditions. For more information, visit Aquestive.com and\nfollow us on LinkedIn\n\nForward Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\napplicable securities laws, including statements regarding LIBERVANT’s\npotential commercial opportunity, contribution to Eton’s growth, anticipated\napproval and launch timing, potential label expansion, patent protection, and\ncommercialization plans, the potential receipt by Aquestive of upfront,\nmilestone and royalty payments, and Aquestive’s manufacture and supply of\nLIBERVANT. These statements reflect current expectations and involve risks and\nuncertainties that could cause actual results to differ materially. These\ninclude delays in or failure to obtain final FDA approval or label expansion;\nchanges in regulatory requirements or the effect of competing products’\nexclusivity; manufacturing or supply constraints; competition, pricing,\nreimbursement, and market acceptance; commercialization costs and execution;\nthe scope, validity, and enforceability of intellectual property rights;\nwhether and when milestone events are achieved, which depend on FDA approvals\nand Eton’s commercialization efforts; the amount of any royalties, which\ndepends on net sales; Eton’s right to terminate the license agreement; and\nAquestive’s ability to meet its supply obligations. Additional risks are\ndescribed in Eton’s and Aquestive’s filings with the Securities and\nExchange Commission. Neither company undertakes any obligation to update these\nstatements except as required by law.\n\nEton Investor Relations:\nLisa M. Wilson, In-Site Communications, Inc.\nT: 212-452-2793\nE: lwilson@insitecony.com\n\nAquestive Investor Relations:\nBrian Korb, astr partners\nbrian.korb@astrpartners.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/db07cafa-b35c-4d61-a1a1-d330caf67ad2)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-14T10:50:00.192304646Z","server_sent_at_ms":1791975000192},"received_at":"2026-10-14T10:50:00.285Z","source_url":null},"analysis":{"id":"156884","press_release_id":"168619","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":["Financial terms (upfront, milestones, royalty rates) not disclosed","Commercialization contingent on final FDA approval and VALTOCO exclusivity expiry"],"eventType":"partnership","narrative":"Aquestive and Eton announced an exclusive U.S. licensing and supply agreement for LIBERVANT (diazepam) buccal film, transferring U.S. commercialization rights to Eton.\n\nEton anticipates commercial availability in April 2027, subject to final FDA approval; full approval in patients 12+ is expected after VALTOCO's orphan exclusivity expires January 10, 2027, and a label-expansion NDA (ages 6-11) has a PDUFA date of March 29, 2027.\n\nFor Aquestive, the deal creates a path to upfront, milestone, and royalty payments plus CDMO manufacturing revenue, addressing a U.S. seizure rescue market the companies size at over $450 million annually.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Aquestive monetizes LIBERVANT via Eton licensing deal — near-term catalysts at Jan 2027 exclusivity expiry and March 2027 PDUFA."},"keyFigures":{"drugName":"LIBERVANT (diazepam) buccal film","customDimensions":{"patent_protection":"into 2038","pdufa_target_date":"March 29, 2027 (age 6-11 label expansion NDA)","anticipated_launch":"April 2027, subject to final FDA approval","us_market_opportunity":"$450 million annually","orphan_exclusivity_expiration_valtoco":"January 10, 2027"}},"quotedText":"Today marks an important new chapter for LIBERVANT and for the epilepsy community","namedEntities":{"people":[{"name":"Sean Brynjelsen","role":"CEO, Eton Pharmaceuticals"},{"name":"Daniel Barber","role":"President and CEO, Aquestive Therapeutics"}],"products":["LIBERVANT (diazepam) buccal film","PharmFilm","Anaphylm (dibutepinephrine) sublingual film","AQST-108 (epinephrine) topical gel","VALTOCO"],"companies":[{"name":"Aquestive Therapeutics, Inc.","ticker":"AQST","relationship":"filer/licensor"},{"name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","relationship":"licensee/partner"}],"dollarAmounts":[{"amount":"$450 million","context":"annual U.S. seizure rescue market opportunity"}]},"materialImpact":{"score":3,"reasoning":"AQST licensed exclusive U.S. rights for LIBERVANT to Eton, securing a path to U.S. commercialization with upfront, milestone, and royalty payments plus CDMO supply revenue. Financial terms were not disclosed, but launch (April 2027, pending FDA approval) creates a new revenue stream for a late-stage asset."},"tickerRelevance":{"others":[{"ticker":"ETON","relevance":"licensee/partner"}],"primary":"AQST"},"globalImportance":35,"audienceRelevance":30,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"licensing deal with undisclosed terms, multi-step regulatory catalysts","householdBrandBoost":0,"retailFavoriteBoost":"AQST has retail following"}},"event_type":"partnership","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Aquestive and Eton announced an exclusive U.S. licensing and supply agreement for LIBERVANT (diazepam) buccal film, transferring U.S. commercialization rights to Eton.\n\nEton anticipates commercial availability in April 2027, subject to final FDA approval; full approval in patients 12+ is expected after VALTOCO's orphan exclusivity expires January 10, 2027, and a label-expansion NDA (ages 6-11) has a PDUFA date of March 29, 2027.\n\nFor Aquestive, the deal creates a path to upfront, milestone, and royalty payments plus CDMO manufacturing revenue, addressing a U.S. seizure rescue market the companies size at over $450 million annually.","key_figures":{"drugName":"LIBERVANT (diazepam) buccal film","customDimensions":{"patent_protection":"into 2038","pdufa_target_date":"March 29, 2027 (age 6-11 label expansion NDA)","anticipated_launch":"April 2027, subject to final FDA approval","us_market_opportunity":"$450 million annually","orphan_exclusivity_expiration_valtoco":"January 10, 2027"}},"named_entities":{"people":[{"name":"Sean Brynjelsen","role":"CEO, Eton Pharmaceuticals"},{"name":"Daniel Barber","role":"President and CEO, Aquestive Therapeutics"}],"products":["LIBERVANT (diazepam) buccal film","PharmFilm","Anaphylm (dibutepinephrine) sublingual film","AQST-108 (epinephrine) topical gel","VALTOCO"],"companies":[{"name":"Aquestive Therapeutics, Inc.","ticker":"AQST","relationship":"filer/licensor"},{"name":"Eton Pharmaceuticals, Inc.","ticker":"ETON","relationship":"licensee/partner"}],"dollarAmounts":[{"amount":"$450 million","context":"annual U.S. seizure rescue market opportunity"}]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-14T10:50:07.213Z","global_importance":35,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"licensing deal with undisclosed terms, multi-step regulatory catalysts","householdBrandBoost":0,"retailFavoriteBoost":"AQST has retail following"}},"durationMs":6832,"modelName":"glm-5.3-flashx"}}